These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 37545132)

  • 41. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
    Chodnicki KD; Prasad S
    Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Kallam A; Vose JM
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.
    Schroeder BA; Jess J; Sankaran H; Shah NN
    Curr Opin Hematol; 2022 Jul; 29(4):225-232. PubMed ID: 35787551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Agrawal V; Murphy L; Pourhassan H; Pullarkat V; Aldoss I
    Eur J Haematol; 2024 Feb; 112(2):236-247. PubMed ID: 37772976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
    Parikh RH; Lonial S
    CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions.
    Wat J; Barmettler S
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):460-466. PubMed ID: 34757064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
    Nagle SJ; Garfall AL; Stadtmauer EA
    Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
    Geyer MB; Brentjens RJ
    Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
    Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.
    Hoogland AI; Barata A; Logue J; Kommalapati A; Hyland KA; Nelson AM; Eisel SL; Small BJ; James BW; Christy SM; Bulls HW; Booth-Jones M; Jayani RV; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
    Transplant Cell Ther; 2022 Jun; 28(6):305.e1-305.e9. PubMed ID: 35378330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
    Rogosic S; Ghorashian S
    Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent Advances in CAR-T Therapy.
    Ali MB
    Cancer Control; 2024; 31():10732748241263713. PubMed ID: 38910268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
    Salaroli A; Spilleboudt C; Bron D; Lewalle P
    Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
    Date V; Nair S
    Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.
    Cerrano M; Ruella M; Perales MA; Vitale C; Faraci DG; Giaccone L; Coscia M; Maloy M; Sanchez-Escamilla M; Elsabah H; Fadul A; Maffini E; Pittari G; Bruno B
    Front Immunol; 2020; 11():888. PubMed ID: 32477359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.